Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Solid Tumors × Nivolumab × Clear all

Phase

Phase 1 3 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 86 Carcinoma, Non-Small-Cell Lung 71 Carcinoma, Renal Cell 41 Neoplasm Metastasis 32 Colorectal Neoplasms 26 Carcinoma, Hepatocellular 26 Squamous Cell Carcinoma of Head and Neck 25 Lung Neoplasms 23 Neoplasms 19 Urinary Bladder Neoplasms 16 Hodgkin Disease 16 Pancreatic Neoplasms 15 Small Cell Lung Carcinoma 14 Sarcoma 14 Breast Neoplasms 14 Prostatic Neoplasms 13 Carcinoma, Transitional Cell 13 Brain Neoplasms 13 Stomach Neoplasms 12 Multiple Myeloma 12 Head and Neck Neoplasms 10 Glioblastoma 10 Esophageal Neoplasms 10 Recurrence 8 Rectal Neoplasms 8 Neuroendocrine Tumors 8 Mesothelioma, Malignant 8 Uterine Cervical Neoplasms 7 Skin Neoplasms 7 Liver Neoplasms 7

Interventions

Paclitaxel 2 Injections 2 tislelizumab 1 osimertinib 1 lazertinib 1 fluzoparib 1 camrelizumab 1 PM 01183 1 Nivolumab 1 Ipilimumab 1 HMPL-013 1 Erlotinib Hydrochloride 1 Dexamethasone 1 Calcium Dobesilate 1 Bortezomib 1 Bevacizumab 1 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03461952 2024-02-22

NIMBLe

Canadian Cancer Trials Group

Phase 2 Terminated

4 enrolled 4 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡